Repository logo
 

B Cell-Activating Factor Neutralization Aggravates Atherosclerosis.

Published version
Peer-reviewed

Type

Article

Change log

Authors

Tsiantoulas, Dimitrios 
Sage, Andrew P 
Göderle, Laura 
Ozsvar-Kozma, Maria 
Murphy, Deirdre 

Abstract

BACKGROUND: Atherosclerotic cardiovascular disease (heart attacks and strokes) is the major cause of death globally and is caused by the buildup of a plaque in the arterial wall. Genomic data showed that the B cell-activating factor (BAFF) receptor pathway, which is specifically essential for the survival of conventional B lymphocytes (B-2 cells), is a key driver of coronary heart disease. Deletion or antibody-mediated blockade of BAFF receptor ablates B-2 cells and decreases experimental atherosclerosis. Anti-BAFF immunotherapy is approved for treatment of autoimmune systemic lupus erythematosus, and can therefore be expected to limit their associated cardiovascular risk. However, direct effects of anti-BAFF immunotherapy on atherosclerosis remain unknown. METHODS: To investigate the effect of BAFF neutralization in atherosclerosis, the authors treated Apoe-/- and Ldlr-/- mice with a well-characterized blocking anti-BAFF antibody. Moreover, to investigate the mechanism by which BAFF impacts atherosclerosis, the authors studied atherosclerosis-prone mice that lack the alternative receptor for BAFF: transmembrane activator and calcium modulator and cyclophilin ligand interactor. RESULTS: The authors demonstrate here that anti-BAFF antibody treatment increased atherosclerosis in mice, despite efficient depletion of mature B-2 cells, suggesting a unique mechanism of action. Indeed, myeloid cell-specific deletion of transmembrane activator and calcium modulator and cyclophilin ligand interactor also results in increased atherosclerosis, while B cell-specific transmembrane activator and calcium modulator and cyclophilin ligand interactor deletion had no effect. Mechanistically, BAFF-transmembrane activator and calcium modulator and cyclophilin ligand interactor signaling represses macrophage IRF7-dependent (but not NF-κB-dependent) Toll-like receptor 9 responses including proatherogenic CXCL10 production. CONCLUSIONS: These data identify a novel B cell-independent anti-inflammatory role for BAFF in atherosclerosis and may have important clinical implications.

Description

Keywords

B-cell activating factor, B-lymphocytes, Transmembrane Activator and CAML Interactor Protein, atherosclerosis, inflammation, Animals, Antibodies, Aorta, Atherosclerosis, B-Cell Activating Factor, Bone Marrow Cells, Chemokine CCL2, Chemokine CXCL10, Cholesterol, Immunotherapy, Interferon Regulatory Factor-7, Macrophages, Mice, Mice, Inbred C57BL, Mice, Knockout, Toll-Like Receptor 9, Transmembrane Activator and CAML Interactor Protein

Journal Title

Circulation

Conference Name

Journal ISSN

0009-7322
1524-4539

Volume Title

138

Publisher

Ovid Technologies (Wolters Kluwer Health)
Sponsorship
British Heart Foundation (None)
British Heart Foundation (CH/10/001/27642)
British Heart Foundation (FS/15/57/31557)
European Research Council (281164)
European Commission (603131)
British Heart Foundation (RG/15/11/31593)
British Heart Foundation (PG/15/76/31756)
This work was supported by grants of the Austrian Science Fund (SFB F54), the European Union (FP7 VIA), the British Heart Foundation, and the European Research Council (ERC). PS is supported by grants from the Swiss National Science Foundation.